ContraFect (CFRX) Enters Warrant Exercise Transaction for Proceeds of $9.6M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. LLY
4. META
5. MSFT
6. SPCX
7. AZN
8. FLG
9. FICO
10. GMAB

Go back to ContraFect (CFRX) Enters Warrant Exercise Transaction for Proceeds of $9.6M

ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million

June 27, 2023 8:30 AM EDT

YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 7.0 million shares of the company's common... More